{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:11:05Z","timestamp":1785370265445,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"LKCMedicine"},{"DOI":"10.13039\/501100001475","name":"Nanyang Technological University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001475","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijpharm.2018.06.017","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T12:40:45Z","timestamp":1528375245000},"page":"368-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart"],"prefix":"10.1016","volume":"547","author":[{"given":"The-Thien","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Vidaillac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie F.L.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Roizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravishankar","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Y.H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teck Boon","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan Liang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Abisheganaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko Siyue","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay H.","family":"Chotirmall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunn","family":"Hadinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2018.06.017_b0005","first-page":"51","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0010","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/AAC.02764-13","article-title":"A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus","volume":"58","author":"Barber","year":"2014","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0015","first-page":"1","article-title":"Chapter 1: Bronchiectasis: epidemiology and causes","volume":"52","author":"Bilton","year":"2011","journal-title":"Eur. Respir. Mon."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0020","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial","volume":"69","author":"Bilton","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0025","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1128\/AAC.49.8.3222-3227.2005","article-title":"Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa","volume":"49","author":"Brazas","year":"2005","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejps.2016.11.011","article-title":"In vitro biopharmaceutical evaluation of ciprofloxacin\/metal cation complexes for pulmonary administration","volume":"97","author":"Brillault","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0040","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0045","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/14656566.2015.1019863","article-title":"Challenges in the development of new therapies for bronchiectasis","volume":"16","author":"Chalmers","year":"2015","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41533-017-0019-9","article-title":"Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults","volume":"27","author":"Chalmers","year":"2017","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/thx.2006.060913","article-title":"Exacerbations in cystic fibrosis: 4. Non-cystic fibrosis bronchiectasis","volume":"63","author":"Chang","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0065","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jcis.2011.10.011","article-title":"Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility","volume":"367","author":"Cheow","year":"2012","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0070","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1378\/chest.09-2996","article-title":"Sputum candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis","volume":"138","author":"Chotirmall","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0080","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21678707.2016.1196129","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"4","author":"De Soyza","year":"2016","journal-title":"Expert Opin. Orphan D"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0085","first-page":"51","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0090","first-page":"1602","article-title":"A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0095","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1586\/14787210.2014.952282","article-title":"Antimicrobial treatment of non-cystic fibrosis bronchiectasis","volume":"12","author":"Grimwood","year":"2014","journal-title":"Exp. Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.colsurfb.2014.02.032","article-title":"Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa","volume":"116","author":"Hadinoto","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0105","article-title":"Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase iii trials (orbit-3 And-4)","volume":"195","author":"Haworth","year":"2017","journal-title":"Am J. Resp. Crit. Care"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0110","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1172\/JCI73469","article-title":"Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure","volume":"124","author":"Henderson","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0115","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1128\/AAC.00808-15","article-title":"Mucin binding reduces colistin antimicrobial activity","volume":"59","author":"Huang","year":"2015","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI11154","article-title":"Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH","volume":"107","author":"Jayaraman","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1753465813487412","article-title":"Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis","volume":"7","author":"Justo","year":"2013","journal-title":"Ther. Adv. Resp. Dis."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0130","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/jps.20697","article-title":"Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine","volume":"95","author":"Konno","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0135","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","article-title":"Non-cystic fibrosis bronchiectasis","volume":"188","author":"McShane","year":"2013","journal-title":"Am. J. Resp. Crit. Care"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1986","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/17425247.2015.1078309","article-title":"Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives","volume":"13","author":"Sugianto","year":"2016","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0155","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","article-title":"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles","volume":"30","author":"Suk","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2018.06.017_b0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy \u2013 barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","article-title":"Prevalence and economic burden of bronchiectasis","volume":"12","author":"Weycker","year":"2005","journal-title":"Clin. Pulm. Med."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013","volume":"14","author":"Weycker","year":"2017","journal-title":"Chron. Resp. Dis."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rmed.2016.06.007","article-title":"Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"117","author":"Wilson","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0180","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","article-title":"Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model","volume":"108","author":"Yang","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.powtec.2015.02.059","article-title":"Mitigating the adverse effect of spray drying on the supersaturation generation capability of amorphous nanopharmaceutical powders","volume":"277","author":"Yu","year":"2015","journal-title":"Powder Technol."},{"key":"10.1016\/j.ijpharm.2018.06.017_b0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2015.12.072","article-title":"Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: spray drying versus spray freeze drying preparation","volume":"499","author":"Yu","year":"2016","journal-title":"Int. J. Pharmaceut."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318304150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318304150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T22:41:40Z","timestamp":1568932900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517318304150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0378517318304150"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.06.017","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}